TERAPIA CELULAR Y MEDICINA REGENERATIVA
Hospital de Jerez
Jerez, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Jerez (8)
2024
-
Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms
British Journal of Haematology
2022
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
2021
-
CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia
CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535
-
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Blood Cancer Journal
2016
-
Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes
PLoS ONE, Vol. 11, Núm. 10
2015
-
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Annals of Hematology, Vol. 94, Núm. 5, pp. 779-787
2005
-
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation
British Journal of Haematology, Vol. 130, Núm. 3, pp. 394-403